I have not been to Europe in several years, but last time I was there, smoking was common. Agree with all of the positive comments, smoking might be a better route into Europe, Bel might work on multiple addictions (good to hear that from some MD's treating patients) and if so, it will be a gold mine for investors.
I once thought Genasense would be a gold mine, but it was not potent enough to downregulate Bcl-2 as was advertised by the fraud CEO. So buyer beware, this is a complex industry fraught with peril, risk, exaggeration and once in awhile great reward- see PCYC for a drug that actually does downregulate Bcl-2.
Ed or Ted is not doing such a great job on SGEN, he has a price target of $26. I will stick with Thomas Wei, he's the only Biotech analyst I trust for accuracy and independence. The others are either inaccurate, or corrupt IMO with 20+ years of following the industry.
Let's hope they are actively engaged and applying pressure for positive change. This is not the type of company that is content with buying and hoping. We need to contact them before future votes to send a message by voting against some dead wood on the BOD.
yes, looks like I will be selling the $5 calls next against my declining stock after the 7.5 calls expire worthless. Should have done more DD before buying this, but at least I kept the loss fairly low (so far).
1) other than Thomas Wei, respected sell-side analyst is a contradiction in terms 2) Agree with Bull analysts have a difficult time admitting they are wrong and 3) some are conflicted by client relationships. SGEN has had several violent price reductions and each one has been a great buying opportunity so far. With the valuation at $5BB the margin for error is low. IMO, not advice.
yes, in the good old days before hedge fund shorts, ETF's and tradebots, IMGN would be up $1-2 on this news. Now they go up slowly and down rapidly. Still in the long run good technology, fundamentals, pipeline and value will eventually be rewarded, it might just take an offer to get a reasonable value.
SGEN's trial results are always stellar...from a jealous IMGN long. SGEN is always a buy on these dips, great company. I wish they would buy IMGN for stock, I will take half a share any day.
If you Google "Sanofi collaboration with Immunogen" you can see the original agreement between the 2 co's was signed in 03, extended in 06, expanded in 08. Not sure when 650984 became part of the deal, the later the better since early terms were not that great and have strengthened over the years. IR should be able to provide some answers, maybe not the exact terms, but when 650...was added.
Here it goes, daily dip trading robot is on again today.
Not seeing this on Yahoo news yet, but the results for this naked antibody are very strong considering it's being used as a single agent in patients that have progresses on other strong meds. This could be a winner. Hopefully, Sanofi will step on the accelerator and get this straight into registration trials. They have not yet identified the MTD, so maybe that's wishful thinking and premature.
CELG and many other leading oncology bio-pharmas are shelling out big bucks to partner with and lend their drug development expertise to smaller biotech's with interesting science and compounds. IMGN employs a VP, Director and at least one other Bus Dev person not doing any Bus Dev. If they are not going to do bus dev, they should slim down, save the money. If they are, they should be signing deals with successful oncology companies like CELG and not wasting time with loser development firms like LLY. Has LLY successfully developed an oncology product? Have they gained approval of anything they developed in the past 10 years? They are almost as bad at drug development as IMGN.
strange day for a big move considering the Puma news and stock move. Not sure it that's a direct competitor to Kadcyla. There's an I-Spy trial going on with Kad and Perjeta, maybe that will also report soon???
the guy is a bean counter with no advanced degree, he would not even be a Finance Director at big pharma, or large biotech. He's probably the most overpaid financial person in Biotech. Not a fan!
It's too early to forecast Bel revs with any accuracy. Maybe by mid-late 2014 the sales potential will be more clear. It's certainly not going to be 2014 and probably not 2015. If sales growth accelerates and they partner the pipeline, so no non-Bel phase III trial costs, my guess is some time in 2016 they get close to B/E, but that's a wild #$%$ guess.
No worries, the technicals were very overbought, rolled over, stocks always go down faster than they go up. Looks for stabilization between here and $6 before the next leg up, absent of any significant news. IMO, sell the $6 Jan or Feb puts here for income.
Not sure I see anything negative here except a lack of understanding from the writer of this foolish article. Anyone who follows the companies, the drugs and the clinical trials can clearly see Roche plans to replace Herceptin with Kadcyla in every possible indication. They are spending, have spent and continue to spend hundreds on millions on clinical trials for Kadcyla.